Dr Daicic was appointed CEO of Atlas Antibodies AB in August 2017, succeeding founding CEO Marianne Hansson. He previously held positions as Acting General Manager, Business Leader and R&D Department Director at GE Healthcare in Uppsala, Sweden, and before that various senior roles at the Institute for Surface Chemistry in Stockholm. John holds a PhD in Physics from the University of Melbourne in Australia and is Associate Professor in Surface Chemistry at the Royal Institute of Technology in Stockholm. John has extensive experience from various leading roles within research and development as well as business development in the Life Science field.
His research interest in Surface Chemistry